Search company, investor...

Founded Year



Series C | Alive

Total Raised


Last Raised

$53M | 3 yrs ago

About Kernel

Kernel is a human intelligence company. The company uses neurotechnology to build a comprehensive portfolio of brain-based biomarkers. It offers brain-based biomarkers to develop new treatments, improve patient care, and optimize brain function. It was founded in 2016 and is based in Culver City, California.

Headquarters Location

Culver City, California, 90232,

United States

(310) 559-8118



Research containing Kernel

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Kernel in 1 CB Insights research brief, most recently on Feb 11, 2021.

Latest Kernel News

Bespoke Treatment Joins Forces with Kernel for Groundbreaking Clinical Study on Depression Treatment

Sep 20, 2023

News Provided By Share This Article Mental Health at Bespoke Treatment Bespoke Treatment, is thrilled to announce its partnership with Kernel, an innovator in non-invasive neuroimaging technology. Working with Kernel on the PREDICT study allows us to double down on our mission of accessibility, leveraging the latest neuroscience to provide individualized care.” — Ben Spielberg, CEO Bespoke Treatment LOS ANGELES, CALIFORNIA, UNITED STATES, September 20, 2023/ / -- Bespoke Treatment, a renowned mental health clinic committed to personalized mental healthcare, is thrilled to announce its partnership with Kernel, an innovator in non-invasive neuroimaging technology. Together, they are embarking on a transformative observational study aimed at identifying biomarkers of depression treatment response using Kernel's revolutionary Flow2 neuroimaging technology. Depression affects millions of individuals and remains a leading cause of disability worldwide. In the United States, rates of depression have been on the rise since 2006, with a concerning increase in suicide rates among teens and young adults. While there are now more treatment options available, ranging from psychotherapy to medication and brain stimulation therapies like Transcranial Magnetic Stimulation (TMS) and Accelerated Transcranial Magnetic Stimulation, finding the right treatment for everyone remains a significant challenge, especially as new treatments emerge. In this landmark study, Bespoke Treatment, in collaboration with Kadima Neuropsychiatry Institute and Clinnova Research Solutions, will leverage the scalable and user-friendly Flow2 technology. The study aims to measure patients as they undergo depression treatments, exploring individual patient-level biomarkers that could pave the way for personalized interventions and more effective depression treatment strategies. The Flow2 is a multimodal brain imaging device, incorporating fNIRS and EEG technology, which tracks functional brain activity using oxygenated and deoxygenated blood similarly to an fMRI machine, but with greater accessibility for everyday practitioners. CEO of Kernel, Ryan Field, expressed his excitement about the partnership, stating, "Our collaboration with Bespoke Treatment is the first step toward building biomarkers for optimal depression treatments, unlocking a new era of precision medicine where treatment decisions are guided by brain measurements and patient outcomes are significantly improved." Bespoke Treatment’s CEO and neuroscientist, Ben Spielberg M.S., also shared his enthusiasm for the study: "Bespoke Treatment is dedicated to making high-quality mental healthcare accessible. Our program integrates cutting-edge science with personalized mental health treatment plans. Working with Kernel on the PREDICT study allows us to double down on our mission of accessibility, leveraging the latest neuroscience to provide individualized care. Moreover, we are excited to contribute to the discovery of biomarkers that will transform depression treatment in the future." The multi-site observational study aims to recruit over 200 individuals initiating new treatments for depression. The data collected through this partnership by Flow2 and analyzed by Kernel's deep learning algorithms are poised to drive innovation and bring us closer to a future where depression treatment is personalized, efficient, and effective. About Bespoke Treatment: Bespoke Treatment, with mental health clinics in Los Angeles, Santa Monica, and Las Vegas, is a renowned for its personalized treatment approaches. The clinic offers a full range of outpatient mental health services, including virtual PHP and IOP, TMS and ketamine therapy , medication management, and routine psychiatry. Their geographically diverse locations ensure that top-tier mental health care is accessible and convenient for a broader range of individuals in these areas. About Kernel: Kernel is a leader in non-invasive neuroimaging technology, dedicated to building robust brain-based biomarkers that drive precision neuromedicine. Their scalable and research-grade data quality neuroimaging technology, Flow2, is set to revolutionize the field of depression treatment. Ben Spielberg, CEO

Kernel Frequently Asked Questions (FAQ)

  • When was Kernel founded?

    Kernel was founded in 2016.

  • Where is Kernel's headquarters?

    Kernel's headquarters is located at Culver City.

  • What is Kernel's latest funding round?

    Kernel's latest funding round is Series C.

  • How much did Kernel raise?

    Kernel raised a total of $153M.

  • Who are the investors of Kernel?

    Investors of Kernel include General Catalyst, Eldridge, Manta Ray Ventures, Tiny Blue Dot Foundation, Khosla Ventures and 3 more.

  • Who are Kernel's competitors?

    Competitors of Kernel include Paradromics and 5 more.


Compare Kernel to Competitors

Neuralink Logo

Neuralink is a brain-chip startup. It develops Brain-Machine Interfaces (BMIs) to connect humans and computers to create devices implanted into the human brain to cure brain disease. It enables an interface between the human brain and computers or other external devices to help people with paralysis. The company was founded in 2016 and is based in Fremont, California.

Paradromics Logo

Paradromics provides data-rate brain-computer interfaces (BCI). It aims to enable treatment options for neurodegenerative diseases and advanced neuroprosthetic limbs for those suffering from amputation and spinal cord injuries. The company was founded in 2015 and is based in Austin, Texas.

Blackrock Neurotech Logo
Blackrock Neurotech

Blackrock Neurotech is a company focused on the development of neurotechnology, specifically in the field of implantable brain-computer interfaces. The company's main offerings include devices that restore function and independence to individuals with neurological disorders, enabling them to perform tasks such as eating, drinking, sending emails, and operating robotic arms using their thoughts. Blackrock Neurotech primarily serves the healthcare and research sectors, with a particular focus on neurological disorders and paralysis. It was founded in 2008 and is based in Salt Lake City, Utah.

Synchron Logo

Synchron operates as a medical device company focusing on the development of minimally invasive neuromodulation technology solutions. It develops an endovascular brain-computer interface that can access every corner of the brain using the blood vessels. It offers Synchron’s switch device to help paralyzed people, such as those with amyotrophic lateral sclerosis (ALS), communicate by controlling computer cursors with their minds. The company was founded in 2016 and is based in Brooklyn, New York.


Naolu Technology (also known as BrainUp) focuses on the application of human brain cutting-edge technologies such as brain-computer interface, early screening of brain health, and artificial intelligence of brain-like decision computing. The firm specializes in-depth in EEG sleep-aid, brain fMRI image analysis and industry real-time brain diagnosis solutions.


NURO develops a neurological platform allowing non-invasive communication and computing control by the brain. It permits any human being to communicate and compute through the brain. The company was founded in 2017 and is based in Waterloo, Canada.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.